Mitochondrial function determines severity but not risk of amyotrophic lateral sclerosis

  • Calum Harvey
  • , Marcel Weinreich
  • , Sai Zhang
  • , Paul J. Hop
  • , Ramona A.J. Zwamborn
  • , Kristel van Eijk
  • , Tom Julian
  • , Tobias Moll
  • , Alfredo Iacoangeli
  • , Ahmad Al Khleifat
  • , John P. Quinn
  • , Abigail L. Pfaff
  • , Sulev Koks
  • , Joanna Poulton
  • , Stephanie L. Battle
  • , Dan E Arking
  • , Michael P Snyder
  • , Project MinE ALS Sequencing Consortium
  • , Jan H Veldink
  • , Kevin P Kenna
  • Pamela J Shaw, Johnathan Cooper-Knock

Research output: Preprint/Working paperPreprint

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. Selective vulnerability of energy-intensive motor neurons (MNs) has fostered speculation that mitochondrial function is a determinant of ALS. Previously, the position of mitochondrial function in the pathogenic cascade leading to neurotoxicity has been unclear. We separated upstream genetic determinants of mitochondrial function, including genetic variation within the mitochondrial genome or autosomes; from downstream changeable factors including mitochondrial copy number (mtCN) and MN gene expression. We discovered that functionally validated mitochondrial haplotypes are a determinant of ALS survival but not ALS risk. Loss-of-function genetic variants within, and reduced MN expression of, ACADM and DNA2 lead to shorter ALS survival; both genes impact mitochondrial function. MtCN responds dynamically to the onset of ALS independent of mitochondrial haplotype, and is also significantly correlated with disease severity. We conclude that mitochondrial function impacts ALS progression but not risk; our findings have therapeutic implications.
Original languageEnglish
PublisherbioRxiv
DOIs
Publication statusPublished - 1 Jun 2022

Fingerprint

Dive into the research topics of 'Mitochondrial function determines severity but not risk of amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

Cite this